The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $46.33

Today's change-0.75 -1.59%
Updated March 31 4:00 PM EDT. Delayed by at least 15 minutes.
 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $46.33

Today's change-0.75 -1.59%
Updated March 31 4:00 PM EDT. Delayed by at least 15 minutes.

Abbott Laboratories crosses below 20-day moving average

Abbott Laboratories closed sharply lower Tuesday, dropping (U.S.)$0.75 or 1.59% to (U.S.)$46.33 and crossing below its 20-day moving average. Shares have lost 1.43% over the last five days, but are unchanged over the last year to date. This security has outperformed the S&P 500 by 9.86% during the last year.

Key company metrics

  • Open(U.S.) $46.83
  • Previous close(U.S.) $47.08
  • High(U.S.) $46.98
  • Low(U.S.) $46.33
  • Bid / Ask(U.S.) $46.31 / (U.S.) $47.23
  • YTD % change+2.91%
  • Volume5,358,141
  • Average volume (10-day)4,733,352
  • Average volume (1-month)5,153,810
  • Average volume (3-month)5,582,782
  • 52-week range(U.S.) $36.65 to (U.S.) $47.88
  • Beta0.66
  • Trailing P/E40.98×
  • P/E 1 year forward21.89×
  • Forward PEG2.39×
  • Indicated annual dividend(U.S.) $0.96
  • Dividend yield2.07%
  • Trailing EPS(U.S.) $1.13
Updated March 31 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+8.50%

Based on its net profit margin of 8.50%, Abbott Laboratories is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.04%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue5,2905,1045,5515,244
Total other revenue--------
Total revenue5,2905,1045,5515,244
Gross profit2,9862,7783,0482,779
Total cost of revenue2,3042,3262,5032,465
Total operating expense4,4814,3734,7904,793
Selling / general / administrative1,7131,5661,7371,739
Research & development346305335387
Depreciation / amortization163132161174
Interest expense (income), net operating--------
Unusual expense (income)-45445125
Other operating expenses, total--------
Operating income809731761451
Interest income (expense), net non-operating-43-35---49
Gain (loss) on sale of assets--------
Other--------
Income before tax802718737423
Income after tax632440460339
Income tax, total17027827784
Net income904538466375
Total adjustments to net income--------
Net income before extra. items632440460339
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items632440460339
Inc. avail. to common incl. extra. items904538466375
Diluted net income904538466375
Dilution adjustment----0--
Diluted weighted average shares1,5221,5201,5171,548
Diluted EPS excluding extraordinary itemsvalue per share0.420.290.300.22
Dividends per sharevalue per share0.240.220.220.22
Diluted normalized EPSvalue per share0.390.310.320.23